Threshold Pharmaceuticals

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 58 in Threshold Pharmaceuticals

  1. The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?Read the original story

    Wednesday Jan 28 | InvestorIdeas.com

    ... million ($242M), Synta Pharmaceuticals Corp. (SNTA:NASDAQ) , with a market cap of about $278M and Threshold Pharmaceuticals Inc. (THLD:NASDAQ) , with a market cap of about $235M. The theme? "They're all oncology companies," Zavoico said. "Synta and ...

    Comment?

  2. "Threshold Pharmaceuticals, Inc. (THLD) - Pharmaceuticals &...Read the original story

    Dec 31, 2014 | PR-inside.com

    Threshold Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops and commercializes therapeutics for the treatment of cancer.

    Comment?

  3. Threshold Pharmaceuticals PT Set at $14.50 by MLV & CoRead the original story

    Dec 19, 2014 | AmericanBankingNews.com

    ... & Co 's price objective suggests a potential upside of 364.74% from the stock's previous close. Threshold Pharmaceuticals ( NASDAQ:THLD ) traded up 0.48% on Friday, hitting $3.135. The stock had a trading volume of 560,298 shares. Threshold ...

    Comment?

  4. Neuroendocrine Tumors - Pipeline Review, H2 2014 - New Market Study PublishedRead the original story

    Dec 15, 2014 | PR-inside.com

    ... Inc., Progenics Pharmaceuticals, Inc., Sompharmaceuticals S.A., Tekmira Pharmaceuticals Corp., Threshold Pharmaceuticals, Inc. About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market ...

    Comment?

  5. Threshold Pharmaceuticals, Inc. Release: Encouraging Initial Data...Read the original story

    Dec 7, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma . The median number of prior therapies was 8 .

    Comment?

  6. Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus...Read the original story

    Dec 6, 2014 | Sys-Con Media

    12/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination ...

    Comment?

  7. New Market Report: Relapsed Multiple Myeloma - Pipeline Review, H2 2014Read the original story

    Dec 2, 2014 | PR-inside.com

    ... , Curis, Inc., Pharmacyclics, Inc., Array BioPharma Inc., MorphoSys AG, Sevion Therapeutics, Inc., Threshold Pharmaceuticals, Inc.,

    Comment?

  8. Recent Study: Neuroendocrine Tumors - Pipeline Review, H2 2014Read the original story

    Nov 30, 2014 | PR-inside.com

    ... Inc., Progenics Pharmaceuticals, Inc., Sompharmaceuticals S.A., Tekmira Pharmaceuticals Corp., Threshold Pharmaceuticals, Inc. About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market ...

    Comment?

  9. Threshold Pharmaceuticals Announces Presentations and Webcasts at...Read the original story

    Nov 25, 2014 | Freshnews

    11/25/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at ...

    Comment?

  10. Threshold Pharmaceuticals, Inc. Announces Phase 1/2 Interim Data...Read the original story

    Nov 18, 2014 | BioSpace

    As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.

    Comment?

  11. Threshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim dataRead the original story

    Nov 17, 2014 | Theflyonthewall.com

    Threshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy.

    Comment?

  12. Relapsed Multiple Myeloma - Pipeline Review, H2 2014 - New Report AvailableRead the original story

    Nov 17, 2014 | PR-inside.com

    ... , Curis, Inc., Pharmacyclics, Inc., Array BioPharma Inc., MorphoSys AG, Sevion Therapeutics, Inc., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp.

    Comment?

  13. Society for NeuroOncology to hold a meetingRead the original story

    Nov 3, 2014 | Theflyonthewall.com

    Threshold Pharmaceuticals receives FDA fast track designation for TH-302 Threshold Pharmaceuticals announced that the FDA granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, or STS. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

    Comment?

  14. FDA Fast Tracks Threshold Pharmaceuticals' Anticancer DrugRead the original story

    Nov 12, 2014 | Pharmaceutical Technology

    Threshold Pharmaceuticals announced on Nov. 11, 2014 that FDA has granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma . Threshold has designed investigational prodrug TH-302 to be activated in hypoxic regions of solid tumors.

    Comment?

  15. Threshold Pharmaceuticals, Inc. Receives FDA Fast Track Designation...Read the original story

    Nov 11, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma . The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

    Comment?

  16. Threshold Pharmaceuticals Receives FDA Fast Track Designation for...Read the original story

    Nov 11, 2014 | Freshnews

    11/11/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated ...

    Comment?

  17. SSF's Threshold Pharmaceuticals, Inc. Snags Fast Track Status For Experimental Cancer Drug TH-302Read the original story

    Nov 11, 2014 | BioSpace

    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma SOUTH SAN FRANCISCO, CA-- - Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma .

    Comment?

  18. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story

    Nov 10, 2014 | Sys-Con Media

    11/10/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. ...

    Comment?

  19. Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in...Read the original story w/Photo

    Nov 6, 2014 | Market Wire

    ... KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S. Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen ...

    Comment?

  20. Threshold Pharmaceuticals, Inc. Reports Third Quarter 2014 Financial And Operational ResultsRead the original story

    Nov 4, 2014 | BioSpace

    Threshold Pharmaceuticals, Inc. , today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million.

    Comment?